Off-the-Shelf immune cell therapy trial opens for tough cancers
NCT ID NCT07410676
Summary
This study is testing a new type of immune cell therapy called EBNK-001 for people with advanced solid tumors that have stopped responding to standard treatments. Participants receive 'off-the-shelf' natural killer (NK) cells from a donor after a short course of chemotherapy, with the goal of seeing if the treatment is safe and shows early signs of fighting the cancer. The trial will test the therapy both alone and in combination with an existing immunotherapy drug (pembrolizumab).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
District One Hospital
RECRUITINGBeijing, Beijing Municipality, 086-373, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.